Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of April 2022, with a specific reporting date of April 14, 2022. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs) with the company.
Key Financial Metrics
The filing does not contain corporate financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share acquisition transactions.
| Transaction Date | Instrument | Transaction Price | Total Volume Acquired | Exchange |
|---|---|---|---|---|
| April 12, 2022 | Ordinary Shares (25p each) | £17.8437 | 23,859.722 shares | London Stock Exchange (XLON) |
Note: The total volume represents the aggregate of 12 individual transactions listed in the filing.
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document solely records the acquisition of shares by executives and their associates.
Guidance, Outlook, and Management Commentary
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The nature of all reported transactions is the "Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 7 April 2022."
Important Facts for Investor Verification
- Transaction Nature: All reported share purchases were automatic dividend reinvestments, not discretionary open-market purchases by executives.
- Participants: Transactions involved 11 individuals, including the CEO (Ms. E. Walmsley), President of Vaccines (Mr. R. Connor), and other senior officers, plus one PCA.
- Uniform Pricing: All transactions executed on April 12, 2022, occurred at the identical price of £17.8437 per share.
- Financial Data Absence: This filing provides no data on GSK's quarterly or annual financial performance; investors must refer to Form 20-F or earnings releases for that information.